SCHEDULE: Vanguard Group Reports 0% Stake in Immunome After Internal Realignment

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Immunome Inc. following an internal corporate realignment.

Summary

• The Vanguard Group filed an Amendment No. 3 to Schedule 13G for Immunome Inc. Common Stock.
• The filing reports 0% aggregate beneficial ownership of Immunome Inc. by The Vanguard Group.
• This change is attributed to an internal realignment at The Vanguard Group, Inc. on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions will now report beneficial ownership separately (on a disaggregated basis).
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these disaggregated subsidiaries and/or business divisions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative update. The change in beneficial ownership to 0% by The Vanguard Group is explicitly attributed to an internal corporate realignment and disaggregation of reporting, not a divestment based on Immunome's performance.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures by institutional investors. A change in reported beneficial ownership by a large entity like The Vanguard Group, especially to 0%, typically indicates an internal restructuring of their reporting rather than a complete divestment, as explicitly stated in the filing. This is a common occurrence for large asset managers with complex organizational structures.

Stakeholder Impact

• Shareholders: May initially perceive a major institutional investor's reported 0% stake as negative, but the explanation clarifies it's an administrative change, mitigating direct negative impact.

Key Dates

Recommendation

This filing is purely administrative, detailing a change in how The Vanguard Group reports its beneficial ownership due to an internal realignment. It does not reflect a change in investment thesis for Immunome Inc. or indicate any operational or financial performance issues. Therefore, a 'hold' recommendation is appropriate as there's no new information to warrant a change in investment position based solely on this filing.

Keywords

Immunome Inc, Vanguard Group, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Corporate Realignment